Central Venous Catheter-Related Infection

This study has been completed.
Sponsor:
Information provided by:
University of Witwatersrand, South Africa
ClinicalTrials.gov Identifier:
NCT00533988
First received: September 21, 2007
Last updated: September 28, 2007
Last verified: September 2007
  Purpose

Intravascular devices are an integral component of modern-day medical practice. Infection is one of the leading complications of intravascular catheters and is associated with an increased mortality, prolonged hospitalization and increased medical costs. Central venous catheters (CVCs) account for an estimated 90% of all catheter-related bloodstream infections (CRBSI). A host of risk factors for CVC-related infections have been documented. This includes most importantly, duration of catheterization. The duration of use of CVCs remains controversial and the length of time such devices can safely be left in situ has not been fully and objectively addressed in the critically ill patient. As a consequence, scheduled replacement remains widely practiced in many Intensive Care Units(ICUs). Over the past few years, antimicrobial impregnated catheters have been introduced in an attempt to limit catheter-related infection (CRI) and increase the time that CVCs can safely be left in place. Recent meta-analyses concluded that antimicrobial impregnated CVCs appear to be effective in reducing CRI. The topic however, remains extremely controversial with different viewpoints appearing in the literature recently.

This was a prospective randomized double-blind study performed in the multidisciplinary ICU at Johannesburg Hospital over a four year period.The study entailed a comparison of standard triple-lumen versus antimicrobial impregnated CVCs on the rate of CRI. The aim was to determine whether the researchers could safely increase the duration of catheter insertion time from the standard practice of seven days to 14 days, to assess the influence of the antimicrobial impregnated catheter on the incidence of CRI, evaluate risk factors and elucidate the epidemiology of CRI.


Condition Intervention Phase
Critically Ill Patients
Infection
Device: Antimicrobial impregnated catheter (5593)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Central Venous Catheter-Related Infection: A Prospective Randomized Double-Blind Study

Further study details as provided by University of Witwatersrand, South Africa:

Primary Outcome Measures:
  • To determine the influence of antimicrobial impregnated catheters on the incidence of catheter-related infection and whether CVCs can safely be left in place for a period of up to 14 days in critically ill patients [ Time Frame: 14 days of catheter placement ]

Secondary Outcome Measures:
  • To elucidate the epidemiology and risks of catheter-related infection in a population of critically ill patients [ Time Frame: 14 day catheter placement ]

Enrollment: 118
Study Start Date: January 1996
Study Completion Date: December 1999
Arms Assigned Interventions
No Intervention: 5592
Standard triple lumen catheter
Active Comparator: 5593
Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
Device: Antimicrobial impregnated catheter (5593)
Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
Other Names:
  • ARROW Standard Triple Lumen Catheter
  • ARROWgard Triple Lumen Catheter

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • critically ill patients likely to require central venous catheter for at least 14 days
  • age 18+ years
  • white cell count on admission > 4 x 10 to 9/L
  • absence of skin burns
  • no history of allergy to sulfa containing preparations
  • consent obtained
  • catheter to be inserted via internal jugular or subclavian veins

Exclusion Criteria:

  • age < 18 years
  • white blood cell count on admission of less than 4 x 10 to 9/L
  • skin burns
  • history of allergy to sulfa-containing preparations
  • guidewire changes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533988

Sponsors and Collaborators
University of Witwatersrand, South Africa
Investigators
Principal Investigator: Mervyn Mer, MBBChFCP(SA) Department of Medicine, Division of Pulmonology and Critical Care, Johannesburg Hospital and University of the Witwatersrand, Johannesburg, South Africa
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00533988     History of Changes
Other Study ID Numbers: 94/4/4.1;7902114
Study First Received: September 21, 2007
Last Updated: September 28, 2007
Health Authority: South Africa: Department of Health
South Africa: Medicines Control Council

Keywords provided by University of Witwatersrand, South Africa:
Central venous catheters
Antimicrobial impregnated catheters
Duration of catheter use
Catheter-related infection
Insertion site
Parenteral nutrition
Critically ill patients (multidisciplinary)

Additional relevant MeSH terms:
Catheter-Related Infections
Communicable Diseases
Critical Illness
Infection
Disease Attributes
Pathologic Processes
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014